Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Temozolomide (Primary) ; Benzylguanine; Carmustine; Filgrastim; Plerixafor
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2018 Planned primary completion date changed from 24 Mar 2018 to 24 Nov 2018.
- 31 Aug 2018 Biomarkers information updated
- 08 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 24 Mar 2018.